Interferon-beta: The neutralizing antibody (NAb) titre predicts reversion to NAb negativity

Multiple Sclerosis

Volumn 10, Issue 5, 2004, Pages 507-510

  Gneiss, C ^a   Reindl, M ^a   Lutterotti, A ^a   Ehling, R ^a   Egg, R ^a   Khalil, M ^a   Berger, T ^a   Deisenhammer, Florian ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Interferon beta; Multiple sclerosis; Neutralizing antibodies

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; VIRUS PROTEIN;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MULTIPLE SCLEROSIS; ORTHOMYXOVIRUS; PREDICTION; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; NEUTRALIZATION TESTS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 4444348797     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1074oa     Document Type: Article

References (22)

1. Wiendl H, Kieseier BC. Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Expert Opin Investig Drugs 2003; 12: 689-712.
2. The IFNB Multiple Sclerosis Study Group, and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-94.
3. PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group, and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001; 56: 1628-36.
4. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
5. Bertolotto A, Malucchi S, Sala A, Orefice G, Carrieri PB, Capobianco M et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002; 73: 148-53.
6. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P et al. for the EVIDENCE (Evidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE Trial. Neurology 2002; 59: 1496-506.
7. The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
8. Rice GPA, Francis GS, and the PRISMS Study Group. Further evidence of dose effect of IFN beta-1a based on neutralizing antibody status. Poster presented at the 11th Annual Meeting of the European Neurological Society; April 21-25, 2001; Paris, France.
9. Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M et al. and the European IFNβ-1a (Avonex) Dose Comparison Study Investigators. A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology 2002; 59: 1507-17.
10. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF et al. for the IMPACT Investigators. Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-87.
11. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al. and the Controlled High Risk Subjects AVONEX® Multiple Sclerosis Prevention Study (CHAMPS) Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904.
12. Herndon RM, Jacobs LD, Coats ME, Goodkin DE, Mass MK, Richert JR et al. Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis. Int J MS Care Dec 1999; 2: 1-6. Retrieved 14 December, 2002, from: http://www.mscare.com
13. Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W et al. and the Multiple Sclerosis Collaborative Research Group (MSCRG). Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998; 50: 1266-72.
14. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999; 52: 1239-43.
15. Giovannoni G, Munschauer F III, Deisenhammer F. Neutralising antibodies to interferon beta during treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 73: 465-69.
16. Rice GPA, Paszner B, Oger J, Lesaux J, Paty D, Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b. Neurology 1999; 52: 1277-79.
17. Pungor E, Files JG, Gabe JD, Do LT, Foley WP, Gray JL et al. A novel bioassay for the determination of neutralizing antibodies to IFN-β1b. J Interferon Cytokine Res 1998; 18: 1025-30.
18. Jilg W, Schmidt M, Deinhardt F, Zachoval R. Hepatitis B vaccination: how long does protection last? Lancet 1984; 2: 458.
19. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-91.
20. Bellomi F, Scagnolari C, Tomassini V, Gasperini C, Paolillo A, Pozzilli C et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 2003; 215: 3-8.
21. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Svenson M, Bendtzen K et al. Neutralizing antibodies against interferon (IFN)-beta reduce the clinical effect in relapsing-remitting multiple sclerosis. Mult Scler 2002; 8: S8.
22. Z Kreuz W, Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M et al. Epidemiology of inhibitors and current treatment, strategies. Haematologica 2003; 88: EREP04. Accessed 12 May 2004. www.haematologica.org